Pharma & Biotech Events & Conferences
Refine Search
Biotechnology
US biotech major Amgen has promised new data from across its oncology innovative medicines and biosimilars portfolio and pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting next week. 27 May 2022
Pharmaceutical
The world’s leading cancer conference kicks off in Chicago on Friday June 3, and for many industry participants, it will be the first time they have attended a medical meeting in person since the pandemic started over two years ago. 25 May 2022
Pharmaceutical
US pharma giant Pfizer has announced detailed results from two pivotal studies that make up the ELEVATE UC Phase III registrational program evaluating etrasimod, a once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator for the treatment of moderately-to-severely active ulcerative colitis (UC). 25 May 2022
Generics
At the 2022 American Psychiatric Association (APA) annual meeting, Israeli generics giant Teva Pharmaceutical will present new data for Austedo (deutetrabenazine). 24 May 2022
Biotechnology
At the annual European Congress of Rheumatology (EULAR 2022), presentations will include new data from two Phase III studies of bimekizumab, BE MOBILE 1 and BE MOBILE 2. 23 May 2022
Pharmaceutical
Full results from the MANDALA Phase III trial have been published by British firms Avillion and AstraZeneca in the New England Journal of Medicine. 16 May 2022
Pharmaceutical
The promising 12-week Phase II data for BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, showed a reduction in the rate of lung function decline in patients with idiopathic pulmonary fibrosis (IPF) will be presented at the American Thoracic Society (ATS) International Conference Breaking News session today (May 16) in San Francisco, 16 May 2022
Biotechnology
Novartis has shared the highlights of the data it will present at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2022 Hybrid Congress. 13 May 2022
Biotechnology
At the annual meeting of the European Society for Pediatric Infectious Diseases (ESPID), Sanofi is presenting results from a pooled analysis of data for nirsevimab. 11 May 2022
Pharmaceutical
At the annual breast cancer congress of the European Society of Medical Oncology (ESMO), Swiss pharma giant Novartis has announced updated median overall survival (OS) results for Kisqali (ribociclib). 4 May 2022
Biotechnology
Norwegian biotech BerGenBio is releasing data today from its Phase IIa bemcentinib COVID-19 clinical trial (BCBC020) in a poster presentation at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), being held both online and in-person in Lisbon, Portugal, from April 23-26, 2022. 25 April 2022
Pharmaceutical
The first treatment to be offered for people with COVID-19 has proven to be of continued use in combating the disease. 25 April 2022
Pharmaceutical
Japanese pharma major Shionogi on Sunday announced new results from two late-breaking presentations of S-217622 at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Lisbon, April 23 – 26. 25 April 2022
Biotechnology
Swiss pharm giant Novartis has announced promising clinical data for JDQ443, an investigational selective, covalent, and orally bioavailable KRASG12C inhibitor at the annual meeting of American Association for Cancer Research (AACR). 13 April 2022
Biotechnology
At 16 weeks, 70% of patients with moderate-to-severe atopic dermatitis (AD) receiving lebrikizumab combined with standard-of-care topical corticosteroids (TCS) achieved at least 75% improvement in overall disease severity (EASI-75) in the ADhere trial. 12 April 2022
Biotechnology
New data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, showing that patients with non-small cell lung cancer (NSCLC) who received the targeted therapy sotorasib experienced extended survival and good quality of life. 11 April 2022
Biotechnology
Anglo-American biotech firm Bicycle Therapeutics’ shares leapt 24.5% by close of trading on Friday, and a further 6.4% to $50.00 in after-hours activity, as it announced positive interim Phase I results from the Phase I/II trial of BT8009, a second-generation BTC targeting Nectin-4. 9 April 2022
Pharmaceutical
Germany’s Bayer has announced late-breaking data from prespecified exploratory subgroup analyses of FIDELITY, a prespecified pooled analysis of the Phase III FIDELIO-DKD and FIGARO-DKD trials. 5 April 2022
Biotechnology
Multiple sclerosis (MS) treatments developed by Biogen (Nasdaq: BIIB) have featured in data presentations at the annual congress of the American Academy of Neurology (AAN). 5 April 2022
Pharmaceutical
AstraZeneca has announced Phase IIb results from the ETESIAN trial that showed AZD8233 reached a statistically-significant and clinically-meaningful reduction (of 73% change) from baseline in low-density lipoprotein cholesterol (LDL-C) levels. 5 April 2022
Biotechnology
Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it released early-stage data on its FT819 in lupus. 19 November 2024
Pharmaceutical
US clinical-stage biopharmaceutical company Boston Pharmaceuticals has announced positive results from a Phase II study evaluating the safety and efficacy of once-monthly efimosfermin alfa (formerly known as BOS-580), a long-acting FGF21 analogue, in participants with stage F2/F3 fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH). 18 November 2024
Pharmaceutical
French drugmaker Ipsen today announced the long-term efficacy and safety of patients treated with Bylvay (odevixibat) from two Phase III open-label extension studies. 18 November 2024
Pharmaceutical
US antiviral giant Gilead Sciences on Friday unveiled two-and-a-half-year interim analysis from the ongoing Phase III ASSURE study of its Livdelzi (seladelpar). 16 November 2024
Pharmaceutical
French drugmaker Ipsen announced late-breaking data for Iqirvo (elafibranor 80mg tablets) from an interim analysis of the ongoing open-label extension of the Phase III ELATIVE study at the American Association for the Study of Liver Disease (AASLD) congress. 16 November 2024
Biotechnology
Belgian drugmaker UCB and US biotech Biogen’s Phase III PHOENYCS GO trial results signal a pivotal development for systemic lupus erythematosus (SLE) treatment, as dapirolizumab pegol met its primary endpoint and demonstrated enhanced disease control and safety at Week 48. 13 November 2024
Biotechnology
Syndax Pharmaceuticals has announced that its Phase II AUGMENT-101 trial of experimental drug revumenib achieved its primary endpoint. 13 November 2024
Pharmaceutical
Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data for its investigational medicine VK2738 at the ObesityWeek meeting. US biotech Beam Therapeutics released early-stage data on its sickle cell disease candidate BEAM-101. Also of note, Arcus Biosciences and Gilead Sciences announced promising Phase III results for their TIGIT inhibitor domvanalimab in combination with zimberelimab. Denmark’s Novo Nordisk released financial results that attracted interest. 10 November 2024
Biotechnology
Shanghai-based BioCity Biopharma has announced promising late-stage results from the Phase II 2-SUCCEED clinical trial of SC0062. 7 November 2024
Biotechnology
Results from the ARC-10 Phase III study of Arcus Biosciences and Gilead Sciences’ domvanalimab and zimberelimab combination therapy indicate a significant reduction in mortality risk for patients with certain advanced lung cancers. 7 November 2024
Biotechnology
Beam Therapeutics will detail new clinical and preclinical data on its sickle cell disease (SCD) therapies at the upcoming American Society of Hematology (ASH) meeting. 6 November 2024
Pharmaceutical
AstraZeneca has presented early results on three experimental weight-loss drugs at the ObesityWeek conference in San Antonio, showing encouraging signs for its obesity pipeline. 5 November 2024
Pharmaceutical
US neuroscience-focused biopharma Neurocrine Biosciences presented new data from more than 300 patients diagnosed with tardive dyskinesia and treated with Ingrezza (valbenazine) capsules at the 2024 Psych Congress in Boston. 5 November 2024
Pharmaceutical
Viking Therapeutics (Nasdaq: VKTX) reported promising early results for its experimental obesity pill, VK2735, with increased weight loss at higher doses. 4 November 2024
Pharmaceutical
The US subsidiary of Israel’s Teva Pharmaceutical Industries has announced new, positive data on social functioning and quality of life from the Phase III subcutaneous olanzapine extended-release injection study (SOLARIS) trial evaluating TEV-'749 in adult patients diagnosed with schizophrenia. 2 November 2024
Biotechnology
UCB has reported Phase IIa data from the TOGETHER (AH0003) study, investigating the safety, efficacy, and tolerability of bepranemab - an investigational anti-tau antibody targeting the mid-region of the tau protein - in people living with prodromal to mild Alzheimer’s disease. 1 November 2024
Biosimilars
The US unit of South Korea-based biosimilar drug developer Celltrion
has announced a late-breaking post hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) of Zymfentra (infliximab-dyyb), during the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting. 30 October 2024
Biotechnology
US pharma major Eli Lilly has released results from two, multi-year, Phase III studies that showed patients treated with mirikizumab sustained stable, long-term remission across two types of inflammatory bowel diseases (IBD), ulcerative colitis (UC) and Crohn’s disease. 28 October 2024
Biotechnology
California’s Vera Therapeutics has released 96-week follow-up results from its ORIGIN Phase IIb trial of atacicept, targeting IgA nephropathy (IgAN). 28 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze